Subscribe to our newsletter.
Copyright 2025 © All rights Reserved Goffin Molecular Technologies
X
- No products in the list
The TRUPCR® PML-RARA Qualitative PCR Test (BCR1, BCR2, BCR3) is for the detection of the PML-RARA t(15;17) translocation is diagnostic for acute promyelocytic leukaemia (APL), although the diagnosis can also be based on morphology. Investigations suggest that 99% of APL patients harbour a translocation between chromosomes 15 and 17, which fuses the retinoic acid receptor alpha (RARA) gene on chromosome 17 with the PML gene on chromosome 15. Detection of the PML-RARA t (15;17) translocation is therefore used within clinical research as an identifier for APL. Depending on the location of breakpoints within the PML site, intron 6, exon 6 and intron 3, the respective PML-RARa transcript subtypes referred to as long (L or bcr1), variant (V or bcr2) and short (S or bcr3), may be formed. They represent 50-55%, 5-10% and 30-40% of the cases respectively.
The TRUPCR® PML-RARA Qualitative PCR Test is an in vitro nucleic acid amplification assay for the qualitative detection of PML-RAR-alpha fusion transcripts in human clinical samples. In this multi-tube assay, extracted RNA is subjected to separate Real-time reverse transcription-polymerase chain reaction (RT-PCR) procedures to detect long, variant and short isoforms simultaneously. An additional amplification for the ABL gene is performed as a control for sample RNA quality.
The TRUPCR® PML-RARA Qualitative PCR Test is a real-time RT-PCR assay developed for the qualitative detection and differentiation of PML-RARA fusion transcripts in bone marrow or peripheral blood samples of patients with acute promyelocytic leukemia (APL/AML-M3). This multi-tube assay identifies the three clinically relevant transcript variants—BCR1 (long form), BCR2 (variant form), and BCR3 (short form)—that arise from the t(15;17) chromosomal translocation. The kit also amplifies the ABL1 gene as an internal control for RNA integrity.
Based on oligonucleotide hydrolysis (TaqMan probe) technology, this assay delivers high specificity and sensitivity, supporting diagnosis, subtyping, and potential treatment response assessment.
Acute promyelocytic leukemia (APL) is a genetically distinct subtype of AML that accounts for 10–15% of all AML cases. Nearly 99% of APL patients carry the t(15;17)(q24;q21) translocation, resulting in a PML-RARA gene fusion. This fusion alters transcriptional regulation and blocks promyelocyte differentiation, driving leukemogenesis.
Depending on the location of the PML gene breakpoint, one of three PML-RARA fusion transcripts is formed:
Recent evidence suggests that the type of fusion transcript may have prognostic and therapeutic implications. For instance, BCR3 is associated with shorter remission duration, while some BCR2 variants may respond less effectively to all-trans retinoic acid (ATRA), especially when the breakpoint lies 5’ to nucleotide 1709. Conversely, 3’ breakpoints in BCR2 may respond to ATRA similarly to BCR1 and BCR3.
The TRUPCR® PML-RARA Qualitative PCR Test allows:
This assay supports diagnosis, transcript typing, and potential response prediction, with fast turnaround and minimal hands-on time.
Product Catalogus
For any missing information or if you require additional details, please do not hesitate to contact us.
Subscribe to our newsletter.